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Abstract
Broad translational success of RNA interference (RNAi) technology depends on the development of effective
delivery approaches. To that end, researchers have developed a variety of strategies, including chemical
modification of RNA, viral and non-viral transfection approaches, and incorporation with delivery vehicles such
as polymer- and lipid-based nanoparticles, engineered and native proteins, extracellular vesicles (EVs), and others.
Among these, EVs and protein-based vehicles stand out as biomimetically-inspired approaches, as both proteins
(e.g. Apolipoprotein A-1, Argonaute 2, and Arc) and EVs mediate intercellular RNA transfer physiologically. Proteins
specifically offer significant therapeutic potential due to their biophysical and biochemical properties as well as their
ability to facilitate and tolerate manipulation; these characteristics have made proteins highly successful translational
therapeutic molecules in the last two decades. This review covers engineered protein vehicles for RNAi delivery
along with what is currently known about naturally-occurring extracellular RNA carriers towards uncovering design
rules that will inform future engineering of protein-based vehicles.
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Background
RNA interference (RNAi) is a well-studied biological
phenomenon that is still emerging as a therapeutic tech-
nology. Discovered by Fire and Mello in 1998, RNAi de-
scribes the silencing of specific protein translation based
on mRNA sequence complementarity of small (~ 19–23 nt)
RNAs such as endogenous microRNA (miRNA) or exogen-
ous small interfering RNA (siRNA) or small hairpin RNA
(shRNA) [1]. RNAi has potentially far-reaching therapeutic
potential due to the central role of aberrant protein
expression in many diseases. Thus far, however, only one
RNAi pharmaceutical, patisiran, has been approved for
clinical use. The major obstacle to further RNAi transla-
tional successes is small RNA delivery to the cytoplasm of
specific cells of therapeutic interest.
The human body has evolved to prevent the unregu-
lated transport of genetic material as a matter of
survival. As a result, numerous biological barriers to
RNAi delivery exist (Fig. 1), including: a) extracellular
RNA-digesting enzymes, b) cellular membranes that re-
pulse charged macromolecules, c) circulating phagocytic
cells, d) clearance by the liver and kidneys, and e) intra-
cellular degradation in the lysosome. These barriers have
necessitated design of RNAi delivery strategies, includ-
ing, prevalently, vehicles such as lipid nanoparticles and
polymer-based systems. Such approaches have been
shown to be effective for delivery to the liver, but can
exhibit immunogenicity and be cleared by the reticulo-
endothelial system.
Alternatively, protein-based RNAi delivery offers a
biomimetic strategy with the potential to overcome
some of the obstacles that hinder synthetic systems for
RNAi therapy. While RNA is trafficked within viruses
and extracellular vesicles (EVs), most naturally occurring
RNA transport is protein-associated or protein-mediated.
Key players include apolipoprotein A-1 (ApoA1) – which
constitutes the primary protein component of high-density
lipoprotein (HDL) – as well as argonaute 2 (Ago2),
activity-regulated cytoskeleton-associated protein (Arc),
and possibly others. Leveraging biological phenomena
involving proteins has already proven to be a successful
formula for therapeutic development as evidenced by the
clinical success of monoclonal antibodies and insulin
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analogs, among many others. In this review, we summarize
the field of protein-based RNAi delivery, including the con-
tribution of protein engineering approaches, and discuss
what challenges and horizons remain for this biomimetic
approach towards unlocking the full therapeutic potential
of RNAi.
Protein-mediated extracellular RNA transport
The critical regulatory roles of small and long-noncoding
RNAs are now well recognized [2, 3], however the concept
of controlled extracellular RNA (exRNA) transport is
more nascent. Figure 2 shows some of the most well char-
acterized (to date) exRNA transporters, including EVs
such as exosomes and microvesicles, and protein carries
such as Ago2, ApoA1, and Arc. In this section, we denote
the highlights of knowledge on these carriers with a focus
on how such information might instruct design of bio-
mimetic RNAi delivery strategies.
Lipoproteins
High density lipoprotein (HDL) is a heterogeneous,
complex circulating particle consisting of mainly phos-
pholipids, cholesterol and proteins, with the primary
protein component (> 70%) being apolipoprotein A-1
(ApoA1). Much has been described about the role of
HDL in cholesterol efflux and its effects on cardiovascu-
lar function, but appreciation of the importance of
HDL in exRNA transport is more recent. In 2011,
Vickers et al. reported that miRNA is found in com-
plex with HDL and showed that the HDL-associated
miRNA in healthy and atherosclerotic patients dif-
fered. HDL was further found to accept miRNA from
macrophage cell line J774 in vitro, with subsequent
capability to deliver miRNA to hepatoma cell line
Huh7 via scavenger receptor class B type 1 (SR-B1)
[4]. Wagner et al. reported that HDL facilitated transport
of low levels (5–10 copies/cell) of miRs to endothelial cells
in vitro [5]. Tabet et al. showed that native HDL delivered
high levels of miR-223, a downregulator of intercellular
adhesion molecule-1 (ICAM-1) mRNA, resulting in
ICAM-1 knockdown in endothelial cells in vitro [6].
Additionally, many studies have examined Low Density
Lipoprotein (LDL) association with miRNA, with the consen-
sus being that levels of miRNA associated with LDL are
much lower than HDL [7]. Meanwhile, a recent study has
observed that a significant amount of lipoprotein-RNA is
non-host derived [8].
HDL delivers cargo via at least one known receptor,
SR-B1, which is widely expressed in macrophages as well
as in tissues such as fat, endothelium, intestines, and
brain (HDL can cross the blood-brain barrier) [9]. The
highest expression occurs in the liver and steroidogenic
tissues that utilize cholesterol for bile and hormone
synthesis, respectively [10]. Expression is also high in
many tumors [11]. SR-B1 binds to HDL and forms a
non-aqueous channel between the lipoprotein and the
Fig. 1 Barriers to RNA delivery. Left: RNA in circulation is vulnerable to RNase degradation and phagocytosis, and access to targeted tissue is
blocked by physical barriers (e.g. endothelial and epithelial layers) and renal and hepatic clearance. Right: Cytoplasmic delivery is impaired by the
plasma membrane, degradation within lysosomes, and nonspecific dsRNA immune activation. The latter can occur within the endosome by
activating a Toll-like receptor (TLR) or in the cytoplasm by activating RIG1 or Protein kinase R (PKR). Images courtesy of Louisa Howard at
Dartmouth University
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plasma membrane, through which lipophilic molecules
can travel bidirectionally (down a concentration gradi-
ent) [10]. Therefore, HDL achieves a direct cytoplasmic
delivery. Controversially, there have been reports that
SR-B1 also mediates HDL endocytosis and resecretion,
potentially playing a role in non-lipid delivery. In hepa-
tocytes, HDL is resecreted deplete of cholesterol, while
in macrophages, HDL is resecreted replete with choles-
terol, indicating that cell type and cholesterol level play
a role in HDL function [12].
There are still open questions as to how miRNA is
taken up, is taken up, bound to, and delivered by HDL,
what the true axis of communication is, and the role of
non-host organism-derived RNA.
Argonaute 2
Argonaute 2 (Ago2) is the catalytic center of the
RNA-Induced Silencing Complex (RISC) that accepts
miRNA and siRNA, protects it from degradation, and
cleaves complementary mRNA in the cytoplasm. Ago2
has been well-studied within the cell, but in 2011,
Arroyo et al. and Turchinovich et al. reported that a
majority of miRNA in circulation was not associated
with vesicles, but rather protein – specifically ~ 100 kDa
Fig. 2 Overview of native extracellular RNA (exRNA) carriers. Unprotected RNAs are rapidly degraded in the extracellular space. Argonaute 2
(Ago2)-miRNA is found in circulation but its secretion mechanism is unknown, and it delivers via the receptor Neuropilin 1 (Nrp1). Apolipoprotein
A-1 (ApoA1) is secreted by mainly the liver and intestine, and interacts with ABCA1, ABCG1, and SR-B1 in peripheral tissue to accumulate
cholesterol and phospholipids. Discoidal nascent High Density Lipoprotein (HDL) is matured into spherical HDL through LCAT, PLTP, and CETP.
Mature HDL is loaded with miRNA through an unknown mechanism. Nascent and mature HDL can interact with SR-B1 to deliver RNA and lipids,
and lipid-free ApoA1 is released back into circulation. Spontaneous lipid transfers also play a large role in HDL function. EVs such as exosomes
and microvesicles deliver RNA, as well as Ago2-miRNA and the retroviral Gag-like protein Arc. Arc has been found to mediate mRNA transport
in the brain; non-exosomal Arc retains function but its prevalence is unknown. ABCA1, ATP-binding cassette subfamily A member 1; ABCG1,
ATP-binding cassette subfamily G member 1; SR-B1, scavenger receptor class B type 1; LCAT, lecithin–cholesterol acyltransferase; CETP, cholesteryl
ester transfer protein; PLTP, cholesteryl ester transfer protein; ARC, activity-regulated cytoskeleton-associated protein
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Ago2 [13, 14]. The distribution of miRNA among the two
fractions was uneven, indicating a sorting mechanism.
Arroyo et al. estimated that potentially 90% of extracellular
miRNA were Ago2-bound. A 2016 paper from Prud’-
homme et al. identified Neuropilin-1 (Nrp1) as a receptor
for extracellular Ago2, and demonstrated functionalized
delivery in multiple cell lines [15]. Nrp1 is also a receptor for
VEGF and Semaphorin 3, among others, and is expressed
widely in endothelial, immune, and many cancer cells, as
well as others, including in the developing brain and heart
[16, 17]. The results above suggest a major intercellular
communication system based on protein-mediated miRNA
delivery. This communication system would be privileged;
endogenous miRNA must compete for Ago2 loading, but
exogenous miRNA would be pre-loaded and ready to per-
form. However, there are currently more questions sur-
rounding extracellular Ago2 than answers. Ago2 secretion
mechanisms are currently unknown, though may be related
to one of many binding partners, such as Hsp90 or Hsc70
[18]. It is also unknown if Ago2 has any mechanism
for targeting specific tissues.
Arc protein
Activity-Regulated Cytoskeleton-Associated protein (Arc) is
a major regulator involved in synaptic plasticity and matur-
ation, learning, and memory [19]. Arc is an early immediate
neuronal gene that regulates synaptic plasticity through
AMPA receptors, which are involved in rapid synaptic trans-
mission. Arc mRNA moves to the dendritic spines where it
is locally translated and begins engaging with the endocytic
machinery to regulate the AMPA receptors [20]. Regulation
of Arc expression is essential for normal cognition and
long-term memory storage. Abnormal Arc expression has
been implicated in various neurological and neurodevelop-
mental disorders such as Alzheimer’s disease, Angelman
syndrome, Fragile X syndrome, and schizophrenia [19]. Pre-
vious studies have noted the similarity between viral proteins
and Arc, as it is composed of structural elements also found
in Group-specific antigen (Gag) polyproteins encoded in
retroviruses and retrotransposons, including human im-
munodeficiency virus type 1 (HIV-1) [21].
In 2018, Pastuzyn et al. and Ashley et al. reported a
novel mechanism by which genetic information (mRNA)
is transferred between neurons via Arc [21, 22]. Arc en-
capsulates mRNA into viral-like capsids for delivery to
neighboring neurons within EVs. When purified in bacter-
ial systems, Arc spontaneously self assembles into oligo-
meric structures with biochemical properties similar to
Gag proteins. Arc capsids are double-shelled structures
measuring 32 nm in diameter and are capable of binding
RNA nonspecifically, which was found to be a requisite
for normal capsid formation. It is hypothesized that Arc is
co-expressed with, and encapsulates and delivers, Arc
mRNA, which may constitute a positive feedback system
of Arc expression. Arc proteins are secreted within EVs,
the uptake of which is thought to be dictated by targeting
moieties on the lipid surface while the capsid itself
protects and transfers the mRNA. It was also shown that
Arc capsids delivered functional mRNA even without EV
encapsulation [21]. Further investigation of this unprece-
dented viral-like mechanism may elucidate understanding
of developments of neurological disorders. Additional
tests must be performed to determine if mRNA binding
truly is nonspecific and if non-encapsulated Arc is truly
functional and non-immunogenic. Finally, the symbiotic
relationship between “human” and “viral” DNA displayed
here raises existential questions about genetic identity.
Non-protein vehicles
While this review does not focus on pathogenic RNA
vectors, other physiologic vectors have significant roles
in exRNA transport, namely EVs. The discovery by
Valadi et al. that EVs (including exosomes, microvesi-
cles, and apoptotic bodies) transfer RNA species opened
a new frontier of knowledge on intercellular communi-
cation [23]. Previously, EVs, which are secreted by most
–if not all– cell types and are prevalent in all body
fluids, were considered a form of cellular waste disposal.
Since Valadi et al., an entire field of studying the natural
pathways of EV biogenesis, composition, and function
has emerged. While much is still unknown about these
heterogeneous vesicles, it is clear that their RNA transfer
capability plays an important role in healthy physiology
as well as pathologic progression. It has also been re-
ported that some EVs may have the ability to target spe-
cific cell types based on their surface proteins [24]. EVs
can also enhance their signaling power by co-delivering
co-factors for RNAi function, such as Ago2 [25]. Further
detail on this topic is outside the scope of this review,
however the reader is referred to excellent recent review
articles for additional information [26, 27].
Engineering of protein-mediated RNA delivery
A feature of protein-based therapeutic systems is
manipulability, or “engineerability.” Many molecular
attributes that contribute to optimal pharmacologic
efficacy – such as low immunogenicity, avoidance of
renal and other forms of clearance, and prevention of
opsonization-mediated phagocytosis and degradation
(Fig. 3) – can be incorporated into proteins via
straightforward genetic engineering techniques. Protein
size, charge, post-translational modification, and binding
affinity to both cargo (e.g. RNA) and target moieties can
all be manipulated using rational design or directed
evolution approaches. For example, conjugation of a
therapeutic protein to the Fc domain or albumin-binding
domain can markedly extend its half-life [28]. These same
domains, along with a variety of others, could also be
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appended to increase protein size, an important determin-
ant of molecular pharmacokinetics. Molecules greater
than 60 kDa avoid renal clearance, while molecular weight
is inversely related to endothelial permeability and tissue
penetrance (and smaller molecules are more highly
influenced by target binding affinity) [29, 30].
With regard to optimizing RNAi delivery, protein-based
vehicles (and all vehicles in general) must accomplish pro-
tection of the RNA strand, evasion of clearance, cell/tissue
targeting, cell penetration, and RNAi lysosomal escape.
Theoretically, this could result in a Rube Goldberg-esque
chimera containing: a) an RNA-binding domain, b) a
tissue-targeting domain, c) an endocytic domain, d) an
endosomolytic domain (this is often added as a second
agent), e) a half-life enhancing domain, and f) multiple
flexible linkers. Unfortunately, any such vehicle would
likely have low translational potential due to its complex-
ity. Thus, attempts at engineering protein vehicles for
small RNA delivery to date have in most cases focused on
more practical approaches, including leveraging biomimi-
cry. Here, we present a summary of the progress in the
field, organized by vehicle RNA-binding domain.
High density lipoprotein
Due to its size, long half-life (5.8 days for ApoA1),
anti-inflammatory nature, and low toxicity, HDL has
recently received attention as drug delivery vehicle,
mainly targeting the liver or tumors [31–33]. Addition-
ally, the amphipathic nature of HDL allows for loading
of hydrophobic, hydrophilic, or amphipathic molecules.
HDL can be isolated from native blood samples (nHDL) or
reconstituted in vitro with recombinant ApoA1 (rHDL),
Fig. 3 Trends in pharmacokinetic behavior of therapeutic proteins. a Glomerular sieving coefficient, which is representative of renal clearance, is
inversely related to molecular weight, so smaller molecules are excreted faster. b Terminal slope of pharmacokinetic profile, which corresponds to rate
of systemic clearance from the body, is inversely related to hydrodynamic radius, so smaller molecules are cleared faster (open dot represents IgG
which utilizes FcRn pathway). c Systemic clearance is related to molecular charge, so more negative molecules are cleared faster (higher pI
corresponds to more negative charge). d Half-life is related to binding affinity, so molecules with worse affinity are cleared faster. Reprinted with
permission pending from [30]. Reproduced with permission from Springer Nature, Journal of Pharmacokinetics and Pharmacodynamics
(Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics, Dhaval K. Shah, copyright (2015)
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most commonly with a cholate method [34]. Reconstitution
has multiple advantages, such as availability and low risk of
contamination, and depending on the lipids used, rHDL
can mimic nHDL at any stage of maturity.
Long before the discovery of miRNA-HDL complexes
in blood, molecular engineers had experimented with
cholesterol-conjugated siRNA and antisense oligonucle-
otides [35–37]. Especially of note is the knockdown of
apolipoprotein B (ApoB) in non-human primates via
chol-siRNA injection in 2006 by Zimmermann et al [38].
In 2007, researchers associated with Alnylam Pharma-
ceuticals published a wide-ranging study of various lipo-
philic siRNA conjugates and their relative efficacy in
murine hepatic delivery [39]. They showed that the
lipophile-siRNAs that preferentially associated with HDL
rather than albumin (or remained unbound) were most
effective in knocking down the target (ApoB) mRNA in
the liver. Strikingly, pre-incubating cholesterol-siRNA
(chol-siRNA) with native HDL before injection led to ~
2- to 4-fold less plasma ApoB (produced in the liver)
when compared to chol-siRNA injected alone. The
authors examined the biodistribution of chol-siRNA,
with greatest uptake in liver, kidney, adrenal, and ovary
tissues. They also demonstrated that HDL-mediated
delivery depends on SR-B1 and, interestingly, lipophilic-siRNA
delivery depends on SidT1, a mammalian homologue to the
Sid1 transmembrane protein that regulates systemic RNA
transport in C. elegans. In 2012, another group associated with
Alnylam, Nakayama et al., compared the liver delivery of
chol-siRNA reconstituted with either recombinant ApoA1 or
apolipoprotein E (ApoE) [40]. ApoE primarily binds to the
LDL Receptor (LDLR), which may have led to greater
liver delivery, and therefore siRNA efficacy, of ApoE-rHDL
over ApoA1-rHDL. The authors also saw that adding 4
chol-siRNA molecules for every 1 rHDL (of either type)
led to siRNA buildup on the plasma membrane in vitro, as
opposed to cytoplasmic buildup seen with 1:1 loading.
This indicates that there may be a limit to how much
siRNA can be loaded using this cholesterol-conjugated
method before it interferes with receptor binding. A
possible solution to this problem was introduced by
Shahzad et al., who applied a different strategy for delivery
of non-cholesterol-conjugated siRNA; they loaded anionic
siRNA into the core of rHDL by neutralizing with cationic
oligolysine peptides [11]. This approach may increase the
siRNA loading capacity of rHDL. The group used siRNA
against STAT3 and FAK in mouse models of ovarian and
colorectal cancer, alone or in combination with che-
motherapeutics. Results showed that in three different
models, including a resistance model, STAT3-rHDL
monotherapy or in combination with docetaxel or
oxaliplatin averaged ~ 72% and ~ 93% decrease in
tumor weight, respectively. Liver function was not im-
pacted and empty rHDL did not affect tumor weight.
Additionally, the authors reported that siRNA was
distributed evenly to 80% of a given tumor after injection. An
analysis by Ding et al., which utilized ApoA1-incorporated
liposomes at a diameter of ~ 90 nm, nevertheless
showed that SR-B1-mediated chol-siRNA uptake is
similar to cholesteryl ester selective uptake [41]. Al-
ternatively, some groups have utilized ApoA1 mimetic
peptides [42–44], gold-templated nanoparticles [45, 46]
and ApoA1-incorporated liposomes [41, 47–50] to
deliver siRNA. This review will not cover those strat-
egies in detail.
There have been relevant attempts to further engin-
eer the HDL molecule for enhanced drug delivery.
Some groups have sought to enhance targeting cap-
abilities by incorporating targeting moieties to HDL
to help direct delivery to the liver [51] or tumor [52].
Some groups have encapsulated various packages
within the core, such as super paramagnetic nano-
particles for guided targeting [53], or hydrophobic
chemotherapeutics [54–56] and Vitamin E [57] for
cancer therapy. Any incorporation or encapsulation
method may increase the size of the rHDL molecule,
which could impact delivery. Additionally, naturally
occurring variants of ApoA1, including the Milano
and Paris mutants, have been discovered. These vari-
ants, R173C and R151C mutants, respectively, per-
form greater cholesterol efflux due to more transient
cholesterol binding [58, 59]. Their behavior in a sys-
tem of siRNA delivery is currently unknown.
Albumin
Human serum albumin (HSA) is the most abundant
protein in blood. It is distributed throughout the blood
circulation and has exceptionally low immunogenicity
and long half-life [60]. Previous success in harnessing
HSA as a drug delivery vehicle makes it attractive for
RNA delivery. HSA, like RNA, is a negatively charged
molecule and the two do not spontaneously interact.
However, Sarett et al. showed that lipophilic
DSPE-PEG-conjugated siRNA was capable of binding
endogenous HSA [61]. In a mouse model, HSA-binding
reduced renal clearance and improved half-life of modi-
fied siRNA, and enhanced delivery to the tumor, achiev-
ing a tumor:liver delivery ratio over 40 (in comparison
to ~ 3 for jetPEI, a cationic polymer). Others have modi-
fied the charge of the albumin to generate electrostatic
attraction with RNA. Han et al. modified the isoelectric
point of bovine albumin with ethylenediamine, making it
positively charged at the pH of blood and able to spon-
taneously form complexes with negative RNA [62]. In
mice, these molecules were distributed primarily to the
lungs (5–12:1 lung:liver delivery ratio) and reduced the
number of lung cancer metastases by over half. Wen et
al. made RNA-HSA complexes by mixing unmodified
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molecules at pH 4, at which HSA is positively charged.
Thermal treatment crosslinked the complexes, which
remained stable at blood pH [63].
p19
The p19 protein of the Tombusvirus genus has been de-
veloped as a siRNA delivery vehicle by a number of
groups, but has not shown success in any in vivo envi-
ronments. Originally detected as function-ambiguous
subgenomic RNA in the tomato bushy stunt plant (and
named for its size), the 19 kiloDalton (kDa) protein was
found to greatly enhance systemic invasion of plants
[64–67]. Voinnet et al. showed that p19 was a viral
counter-defense to posttranscriptional gene silencing
(PTGS), the analogue of RNAi in the plant kingdom
[68]. Further studies elucidated that p19 dimers select-
ively bind to small double-stranded RNA (dsRNA) ~ 19–
21 bp in length with subnanomolar affinity, behaving as
a “molecular caliper” [69–71]. Engineering of the p19
protein began with Cheng et al. enhancing dsRNA affin-
ity by linking two p19 monomers [72]. Choi et al. fused
the ephrin mimetic peptide YSA to p19 monomers to ef-
fectively target siRNA to EphA2-expressing cancer cells
in vitro [73]. This group saw a ~ 6- to 36-fold extension
of siRNA half-life in 30% serum when first incubated
with p19-YSA. Additionally, they saw protein-RNA dis-
sociation at endosomal pH. Danielson et al. fused a
cell-penetrating Tat peptide to p19 dimers, and saw sub-
stantial knockdown in vitro only when co-treated with
cell-penetrating endosomolytic compound E5-TAT [74].
Yang et al. performed yeast-display directed evolution on
p19, ultimately finding a double mutant with 160-fold
greater binding affinity [75]. The p19 monomers were
then fused to an EGFR-targeting domain and added to
cells in vitro, along with an EGFR-targeting endosomoly-
tic compound. Experiments showed that higher affinity
led to greater silencing efficacy. The authors attributed
this to increased uptake as well as enhanced intracellular
pharmacodynamics.
Antibodies
Some designs have utilized antibodies as targeting moi-
eties for specific delivery, but others have conjugated
RNA directly to antibodies themselves [76]. Cuellar et
al. utilized THIOMAB antibodies covalently bound to
siRNA to form antibody-siRNA conjugates [77]. These
antibodies are referred to as THIOMABs since they con-
tained an exposed cysteine residue on each heavy chain
to which the cargo was attached, allowing for production
of homogeneous antibody-drug conjugates [78]. These
constructs targeted tumor cells in mice, but were limited
by endosomal entrapment and intracellular clearance.
Xia et al. used streptavidin-conjugated antibodies and bi-
otinylated siRNA to deliver in vitro, but also saw issues
with endosomal degradation [79]. Sugo et al. conjugated
thiol-reactive siRNA to a single-chain variable fragment
(scFv) antibody for CD71 in order to deliver to mouse
heart and skeletal muscle [80]. Remarkably, they ob-
served persistent knockdown (30 and 62%, respectively)
even one month later.
PKR
Protein Kinase R (PKR) is an interferon-induced kinase
that is a key component in the antiviral innate immune
pathway in eukaryotes. PKR is activated by double
stranded viral RNAs, a byproduct of transcription in
RNA/DNA viruses. Once activated, PKR phosphorylates
eukaryotic initiation factor-2, which inhibits translation
of viral proteins and subsequent viral spread.
PKR is one of the well-studied proteins with canonical
dsRNA binding motifs. The protein contains two dsRNA
binding domains (DRBD), one at the N- terminus and
one at the C-terminus connected by a long linker [81].
The DRBDs consist of two tandem binding motifs,
dsRBM1 and dsRBM2 joined by a 20-residue linker to
form the αβββα fold. It is thought that dsRNA binds to
PKR in a sequence independent manner. The crystal
structure shows the protein spanning 16 bp of the
dsRNA and primarily interacting with 2′-hydroxyls and
the phosphate backbone of the dsRNA [82].
Eguchi et al. developed the fusion protein PTD-DRBD,
now commercially known as Transductin, comprised of
the PKR binding domains and a Tat peptide that showed
effective siRNA delivery in various cell lines. However, in
vivo studies showed an observed non-specific cell
uptake, which caused several side effects [83]. It was
therefore thought that replacing the Tat sequence with a
receptor ligand would allow for specific targeting.
Geoghegan et al. replaced the Tat peptide with B2 pep-
tide sequence that binds to a recombinant transferrin re-
ceptor. The fusion protein was shown to effectively
knockdown HPRT in HeLa cells and showed TfR
mediated uptake. It was also noted that knockdown was
enhanced with chloroquine suggesting the endosomal
entrapment of the complexed protein [84]. In 2014, Lui
et al. developed a multiagent siRNA delivery system
consisting of the dsRBD domain, an EGFR clustering
domain, and a pore-forming protein Perfringolysin O
(PFO) domain to induce endosomal escape. The delivery
system showed efficient silencing in vitro but did not
achieve delivery in vivo due to the dissociation of the
siRNA from the protein [85].
Viral vectors and virus-like particles
~ 70% of gene therapy clinical trials have utilized modi-
fied viruses, starting in 1989, before the discovery of
RNAi [86]. Some viruses deliver genetic material for
transient expression, while others integrate into the
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genome, allowing for long-term expression. Long-term ex-
pression is usually preferred, though when coupled with
broad tropism (which many viruses exhibit) can be danger-
ous [87]. Additionally, genome integration can be carcino-
genic [88]. Furthermore, in one case, extended genomic
expression of exogenous shRNA in the liver consistently
led to fatality in mice due to saturation of RNAi machinery
[89]. Other concerns that have cooled interest in viral deliv-
ery are potential immunogenicity, viral sequence mutation,
and difficulty in large-scale manufacture [90, 91]. However,
there are also advantages to using viral vectors. Viruses
have been evolutionarily honed for delivery to the mamma-
lian cell cytoplasm (and nucleus), and they do so extremely
efficiently and in low doses. Additionally, viruses have re-
cently been approved by the FDA for multiple diseases: the
treatment of inoperable melanoma, as an ocular gene deliv-
ery vehicle for hereditary retinal dystrophy, and for the
transfection of chimeric antigen receptor T-cells. There are
many reviews that focus on viral vectors for gene delivery
[92–94]. There have been strategies to improve viral mole-
cules for targeting, including pseudotyping and introducing
adaptor and binding domains [87, 95]. Other attempts to
optimize viral vectors as drug delivery vehicles are ongoing
as well [96, 97].
Heterologous expression of the major structural pro-
teins of viruses leads to the self-assembly of virus-like
particles (VLPs). VLPs have similar structural formation
of the parental virus without any secondary proteins or
genomic data, and thereby forego some of the concerns
with viral delivery discussed above. Unlike viruses, VLPs
can be produced in high-yield expression systems such
as E. coli or insect cells and are more easily manipulable.
All VLPs discussed here are ~ 24–40 nm in diameter. A
common strategy available with some VLPs is encapsula-
tion of cargo via disassembly-reassembly, whereby re-
duction of disulfide bonds leads to VLP dissociation and
dialysis into a oxidizing environment in the presence of
nucleic acids leads to packaging [98]. Bousarghin et al.
utilized this strategy with a VLP based on human papil-
lomavirus virus (HPV) capsid protein L1, and encapsu-
lated plasmid DNA that expressed shRNA [99]. This
shRNA targeted p53-inhibiting proteins, and halved
tumor weight in a mouse model of HPV-caused cervical
cancer. The same disassembly-reassembly strategy was
used in VLPs based on JC virus by two different groups
[100, 101]. Chou et al. injected VLPs containing IL-10
shRNA into mice along with immunogenic LPS, and saw
a massive reduction of IL-10 and TNF-α in the blood-
stream, by 93 and 81%, respectively, and improved
mouse survival. Hoffmann et al. performed extensive in
vivo studies looking at delivery of VLP-siRNA to the tibia
and lumbar vertebrae in mice. They observed up to a 40%
decrease in RANKL mRNA that was dose-dependent
and sustained with multiple injections.
A second strategy is to encapsulate the RNA through
binding to the internal face of a capsid. Often, as in the
case of the coat protein from bacteriophage MS2, the
VLP will only form when stabilized by the presence of
specific RNA sequences. Ashley et al. co-packaged four
different siRNA molecules (~ 84 molecules/VLP) into
MS2 VLPs, finding that a specific sequence was not re-
quired for them [102]. They also conjugated a peptide
for targeting and saw a remarkable increase in endocytic
specificity in vitro. Pan et al. packaged pre-miR-146a into
MS2 VLPs using a specific sequence called a pac site and
then conjugated a TAT peptide [103]. In mice, they saw al-
most equal concentration of the miRNA in plasma, lung,
spleen, and kidney. Galaway et al. packaged siRNA into
MS2 VLPs using a specific “TR” sequence, and later con-
jugated transferrin for targeting [104]. Fang et al. used a
specific hairpin to load miR-30 into a VLP derived from
the bacteriophage Qβ [105]. A third strategy was
employed by Choi et al., wherein they made a chimera of
truncated Hepatitus B Virus (HBV) capsid protein, RGD
peptide (for targeting), and p19 (for RNA binding) [106,
107]. This construct greatly reduced tumor size in a
mouse model. A fourth strategy involves nano-scale
self-assembled protein structures that are not virally de-
rived: nanocages. In work by Lee et al., each ferritin-based
nanocage was designed to display 24 polypeptides with
the following constitution: lysosome-exclusive cleavable
peptide – cationic protamine-derived peptide (which
associated with siRNA) – EGFR-targeting affibody –
cell-penetrating Tat peptide [108]. Likewise, Guan et al.
designed a heat shock protein-based nanocage that
displayed an arginine-rich peptide for cell penetration
(see below) [109].
Naturally-occurring cationic peptides
Cationic peptides that have been used for small RNA de-
livery have been covered by Shukla et al. [110]. In gen-
eral, vehicles that display a high concentration of
positive charge often suffer due to high retention in all
tissues, including those that are not being targeted [111,
112]. Here we briefly discuss naturally-occurring cationic
peptides. Protamine is a naturally-occuring peptide with
a high percentage of arginine (67%) that is FDA ap-
proved. In nature, protamine condenses DNA of fish
sperm for delivery to the nucleus of an egg. This prop-
erty has led to research into its potential as an siRNA
carrier. In one attempt, siRNA as well as cholesterol
were condensed by protamine into a nanocomplex that
showed preferential endocytosis into liver cells in vitro
[113, 114]. Protamine has also been fused to antibodies
and antibody fragments for targeted siRNA delivery to
tumors, and shown inhibition of tumor genes in mouse
models [76, 115–117]. Some groups have also utilized
atelocollagen, which is collagen treated with pepsin, as a
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small RNA delivery vehicle [118–121]. Other groups
have used gelatin, another collagen derivative.
Cell-penetrating and Endosomolytic peptides
Much focus has been directed at devising simple pep-
tides for cytoplasmic delivery of siRNA. Cell-penetrating
and endosomolytic peptides interact with the plasma
membrane or the endosome membrane, respectively, in
a biophysical manner in order to pass through the
bilayer. These peptides are most effectively used in
conjunction with targeting moieties since they are non-
specific and will interact with any cell type. This promis-
cuity contributes to their overall toxicity [122]. There
have been a number of reviews on these peptides in the
context of siRNA delivery [123–125]. Briefly, cationic
arginine-rich peptides, such as the Tat peptide, interact
with negatively charged phospholipids on the cell surface
and can create transient pores in the membrane. Amphi-
pathic peptides insert themselves into the lipid bilayer
and can traverse the plasma membrane in this manner.
These mechanisms are also related to endocytosis, how-
ever, and can lead to accumulation in the endosome
[122]. Endosomolytic peptides are specifically designed
to be reactive to the low pH environment. Fusogenic
peptides change confirmation to become amphipathic
helices which fuse to and disrupt the endosome. Some
peptides have masked reactive moieties that are revealed
through a pH-sensitive chemical reaction. Proton buffer-
ing peptides have weak bases and act as a proton
sponge, accumulating protons and causing osmotic
swelling and/or rupture. Some light-activated peptides
have even been developed for endosomolytic escape.
There are ongoing attempts to design peptides that
exhibit both cell-penetrating and endosomolytic capabil-
ities [126].
Conclusions
Further knowledge development on the natural pathways
of RNA communication between cells would inform
novel biomimetic therapeutic RNAi delivery strategies.
In the current landscape, the study of EVs in this role
has eclipsed the study of other biological vehicles, how-
ever other natural vehicles are important to study if only
to understand the limitations of EV-mediated transport.
Important questions to ask are: 1) why have we evolved
multiple miRNA transport mechanisms?; 2) are these re-
dundant pathways?; and 3) what is the axis of communi-
cation for each of these vehicles?
Additionally, understanding the various functions of
each of the natural vehicles would inform design of
engineered RNAi delivery. The initial discovery by
Valadi et al. of physiological RNA transport through
EVs led to work by Alvarez-Erviti et al. which delivered
exogenous siRNA to the mouse brain, and many further
works [23, 127]. Indeed, in a few short years the EV
research field has ballooned; now there are studies on
both diagnostics and therapeutic delivery for a bevy of
diseases. In a broader sense, however, scientists have
been studying synthetic EVs for drug delivery since the
1970s in liposomes and lipid nanoparticles. The potency
of lipid-based drug delivery seems obvious in retrospect;
given what we now know about the natural pathways
of EV-mediated delivery, we can refer to lipid systems
as biomimetic.
Biomimicry is particularly effective in that it can in-
corporate therapeutic factors that we cannot yet design
rationally. In the case of noncovalent protein-based
RNAi delivery, affinity of the carrier for the RNA is an
important factor for stability in circulation (and intracel-
lularly), and scientists have sought to enhance delivery
efficiency by enhancing affinity. For example, Yang et al.
enhanced the binding affinity of p19 for dsRNA through
yeast display to a dissociation constant (kd) of 11 pM
[75]. Contrast this with the reported affinity of ~ 72 nM
for Ago2 and ssRNA, and it remains unclear why Ago2
would retain stability in circulation and other constructs
would not [128]. In reality, however, the process of Ago2
binding to RNA has been described as “irreversible,” and
the half-life for the complex may be days or weeks in
vitro [129, 130]. Is such intra-vehicular affinity required
for successful delivery? It is clear we need to research
specific problems in noncovalent RNAi delivery to begin
to understand the role of factors like affinity.
Additionally, further research needs to be done on the
pharmacokinetic and pharmacodynamic tools of analysis
of protein-based RNAi treatment. While this is true of
protein therapeutics in general [131], small RNA delivery
poses its own unique challenges. Efficacy is dependent
on efficient cytoplasmic delivery to the proper cells
(followed by additional processing). The downstream ef-
fects of various small RNA are divergent by definition,
but normative methods of relating small RNA to mRNA
to protein levels over a given time will provide tools for
devising doses and time courses and analyzing pharma-
cokinetic profiles for definition of a therapeutic window.
Toxicology for small RNA is also very important but
complex, as deleterious effects are likely sequence- and
organ-specific. However, clever models like a transgenic
mouse that expresses fluorescent protein in the presence
of small RNA can simplify biodistribution studies [132].
The pharmacological rules governing small RNA efficacy
would likely inform iterative vehicle design.
Proteins are inherently unstable and complex molecules.
In production, they are subject to various unintentional
processes which render them ineffective: heterogeneity,
chemical and enzymatic hydrolysis, crosslinking/aggrega-
tion, side-chain modification, irreversible conformation
changes, unfolding, and others. They are sensitive to pH,
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temperature, ionic concentration, and other formulation
properties. In vivo, they are vulnerable to proteases in
circulation and are highly bioactive and thus likely to
produce unintended effects. The specific factors that are cur-
rently limiting protein-RNA vehicles are construct-dependent,
but in general include instability in circulation, rapid
clearance, inability to circumvent endosomal degrad-
ation, and nonspecific delivery. It is our hope that by
increasing understanding of physiological exRNA
transport and taking seriously pharmacokinetic re-
straints, protein-based RNAi delivery vehicles could
overcome current limitations and push RNAi thera-
peutics further into the clinic.
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